<?xml version="1.0" encoding="utf-8"?><xliff xmlns:sdl="http://sdl.com/FileTypes/SdlXliff/1.0" xmlns="urn:oasis:names:tc:xliff:document:1.2" version="1.2" sdl:version="1.0"><file original="C:\Users\134\Desktop\Translatrix\HKI_test-set_EN-FI\en-GB\en-test-1-totranslate\segment_04_en\dailymail.co.uk.170665.txt" datatype="x-sdlfilterframework2" source-language="en-GB" target-language="fi-FI"><header><file-info xmlns="http://sdl.com/FileTypes/SdlXliff/1.0"><value key="SDL:FileId">893cabad-2c63-4dda-bd35-f07211996c12</value><value key="SDL:CreationDate">10/24/2016 10:19:05</value><value key="SDL:OriginalFilePath">C:\Users\134\Desktop\Translatrix\HKI_test-set_EN-FI\en-GB\en-test-1-totranslate\segment_04_en\dailymail.co.uk.170665.txt</value><value key="SDL:OriginalEncoding">Windows-1252</value><value key="SDL:AutoClonedFlagSupported">True</value><value key="HasUtf8Bom">False</value><value key="LineBreakType">
</value><value key="ParagraphTextDirections"></value><sniff-info><detected-encoding detection-level="Likely" encoding="Windows-1252"/><detected-source-lang detection-level="Guess" lang="en-GB"/><props><value key="HasUtf8Bom">False</value><value key="LineBreakType">
</value></props></sniff-info></file-info><sdl:filetype-info><sdl:filetype-id>Plain Text v 1.0.0.0</sdl:filetype-id></sdl:filetype-info><tag-defs xmlns="http://sdl.com/FileTypes/SdlXliff/1.0"><tag id="0"><st name="^">^</st></tag><tag id="1"><st name="$">$</st></tag><tag id="2"><st name="^">^</st></tag><tag id="3"><st name="$">$</st></tag><tag id="4"><st name="^">^</st></tag><tag id="5"><st name="$">$</st></tag><tag id="6"><st name="^">^</st></tag><tag id="7"><st name="$">$</st></tag><tag id="8"><st name="^">^</st></tag><tag id="9"><st name="$">$</st></tag><tag id="10"><st name="^">^</st></tag><tag id="11"><st name="$">$</st></tag><tag id="12"><st name="^">^</st></tag><tag id="13"><st name="$">$</st></tag><tag id="14"><st name="^">^</st></tag><tag id="15"><st name="$">$</st></tag><tag id="16"><st name="^">^</st></tag><tag id="17"><st name="$">$</st></tag><tag id="18"><st name="^">^</st></tag><tag id="19"><st name="$">$</st></tag><tag id="20"><st name="^">^</st></tag><tag id="21"><st name="$">$</st></tag><tag id="22"><st name="^">^</st></tag><tag id="23"><st name="$">$</st></tag><tag id="24"><st name="^">^</st></tag><tag id="25"><st name="$">$</st></tag><tag id="26"><st name="^">^</st></tag><tag id="27"><st name="$">$</st></tag><tag id="28"><st name="^">^</st></tag><tag id="29"><st name="$">$</st></tag><tag id="30"><st name="^">^</st></tag><tag id="31"><st name="$">$</st></tag><tag id="32"><st name="^">^</st></tag><tag id="33"><st name="$">$</st></tag><tag id="34"><st name="^">^</st></tag><tag id="35"><st name="$">$</st></tag></tag-defs></header><body><trans-unit translate="no" id="dfcefc54-7653-4800-a802-57b81e067398"><source><x id="0"/></source></trans-unit><trans-unit id="6cdc3b1b-1750-451a-9f30-c94207257d2a"><source>The Â£2-a-day drug that can cut heart attack threat</source><seg-source><mrk mtype="seg" mid="1">The Â£2-a-day drug that can cut heart attack threat</mrk></seg-source><target><mrk mtype="seg" mid="1">Kaksi puntaa päivässä maksava lääke voi vähentää sydänkohtauksen riskiä</mrk></target><sdl:seg-defs><sdl:seg id="1" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">DAr0rHBkM0ULHlB8nTbZvoqOuqg=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/09/2017 11:25:03</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/09/2017 11:25:03</sdl:value><sdl:value key="SDL:OriginalTranslationHash">-67214305</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="b44cc20b-2f8b-4b13-80f7-8abe43cfc107"><source><x id="1"/>
<x id="2"/></source></trans-unit><trans-unit id="aa106802-f8ca-4a6e-a234-f0c0248b7671"><source>Thousands of heart attack patients are to benefit from a Â£2-a-day drug, after officials recommended it be given to more people for longer.</source><seg-source><mrk mtype="seg" mid="2">Thousands of heart attack patients are to benefit from a Â£2-a-day drug, after officials recommended it be given to more people for longer.</mrk></seg-source><target><mrk mtype="seg" mid="2">Tuhannet sydänkohtauspotilaat ovat hyötymässä kaksi puntaa päivässä maksavasta lääkkeestä sen jälkeen, kun viranomaiset suosittelivat, että sitä annetaan ihmisille pidempään.</mrk></target><sdl:seg-defs><sdl:seg id="2" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">FJztSg4jsF6pc2oRUOmUHZqUQEI=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/09/2017 11:28:14</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/09/2017 11:28:14</sdl:value><sdl:value key="SDL:OriginalTranslationHash">-1530693122</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="19d69be0-b2cd-48f9-a699-ae08393959cf"><source><x id="3"/>
<x id="4"/></source></trans-unit><trans-unit id="b4491b2e-c971-4223-adc9-ba06f48bf513"><source>Anti-clotting drug ticagrelor slashes the risk of repeat attacks for people with heart disease.</source><seg-source><mrk mtype="seg" mid="3">Anti-clotting drug ticagrelor slashes the risk of repeat attacks for people with heart disease.</mrk></seg-source><target><mrk mtype="seg" mid="3">Veren hyytymistä estävä lääke, ticagrelor, pudottaa uusiutuvien kohtausten riskiä ihmisillä, joilla on sydänsairaus.</mrk></target><sdl:seg-defs><sdl:seg id="3" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">/MgzhCPt1mKhiOgsbE5mqWrYPyY=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/09/2017 11:29:33</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/09/2017 11:29:33</sdl:value><sdl:value key="SDL:OriginalTranslationHash">-42631445</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="b3f18d26-5064-4081-82d5-959ce495a6e4"><source><x id="5"/>
<x id="6"/></source></trans-unit><trans-unit id="7cc5a8ea-dda9-4035-8251-1440e3eeabe4"><source>The drug is already given for 12 months after a heart attack, reducing the risk of a stroke or another attack.</source><seg-source><mrk mtype="seg" mid="4">The drug is already given for 12 months after a heart attack, reducing the risk of a stroke or another attack.</mrk></seg-source><target><mrk mtype="seg" mid="4">Lääkettä annetaan jo 12 kuukauden ajan sydänkohtauksen jälkeen, jotta aivohalvauksen tai toisen kohtauksen riski laskee.</mrk></target><sdl:seg-defs><sdl:seg id="4" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">SY4yCd6pi1EGX2XjJt7zIIhA8p4=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/09/2017 11:30:30</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/09/2017 11:30:30</sdl:value><sdl:value key="SDL:OriginalTranslationHash">-821766902</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="96ea93d2-4f13-4c59-96da-e5c56371ea3d"><source><x id="7"/>
<x id="8"/></source></trans-unit><trans-unit id="c9325b0b-8f25-45cd-8823-70adb19e0676"><source>NHS watchdog NICE has advised that it should be given to people for four years, to further reduce the risk of cardiovascular problems.</source><seg-source><mrk mtype="seg" mid="5">NHS watchdog NICE has advised that it should be given to people for four years, to further reduce the risk of cardiovascular problems.</mrk></seg-source><target><mrk mtype="seg" mid="5">NHS:n valvoja NICE on neuvonut, että sitä pitäisi antaa ihmisille neljän vuoden ajan, jotta voitaisiin yhä laskea sydän- ja verisuoniongelmien riskiä.</mrk></target><sdl:seg-defs><sdl:seg id="5" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">SGUd3nYd5V+fyUEDqvqTT22L1ds=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/09/2017 11:31:28</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/09/2017 11:31:28</sdl:value><sdl:value key="SDL:OriginalTranslationHash">21403705</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="834df2c8-f345-4e84-aec1-17236b076125"><source><x id="9"/>
<x id="10"/></source></trans-unit><trans-unit id="c0c41f9f-95b1-4621-9040-24bc640b878d"><source>But now NHS watchdog NICE has advised that it should be given to people for four years, to further reduce the risk of cardiovascular problems.</source><seg-source><mrk mtype="seg" mid="6">But now NHS watchdog NICE has advised that it should be given to people for four years, to further reduce the risk of cardiovascular problems.</mrk></seg-source><target><mrk mtype="seg" mid="6">Mutta nyt NHS:n valvoja NICE on neuvonut, että sitä pitäisi antaa ihmisille neljän vuoden ajan, jotta voitaisiin yhä laskea sydän- ja verisuoniongelmien riskiä.</mrk></target><sdl:seg-defs><sdl:seg id="6" conf="Translated" origin="interactive" percent="94"><sdl:prev-origin origin="tm" origin-system="News_EN-FI" percent="94"><sdl:prev-origin/><sdl:value key="SegmentIdentityHash">CTNQ4dMFsl04jrZkA2Oh2d+ndIc=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/09/2017 11:30:31</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/09/2017 11:31:28</sdl:value></sdl:prev-origin><sdl:value key="SegmentIdentityHash">CTNQ4dMFsl04jrZkA2Oh2d+ndIc=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/09/2017 11:31:38</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/09/2017 11:31:38</sdl:value><sdl:value key="SDL:OriginalTranslationHash">-301928928</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="7d30de52-9a01-4f9f-84d3-ac7ad2d89724"><source><x id="11"/>
<x id="12"/></source></trans-unit><trans-unit id="ad64b910-4e92-4a79-aed1-0d1138bda999"><source>Some 140,000 people have a heart attack in England every year, and a quarter of these go on to have another attack or a stroke.</source><seg-source><mrk mtype="seg" mid="7">Some 140,000 people have a heart attack in England every year, and a quarter of these go on to have another attack or a stroke.</mrk></seg-source><target><mrk mtype="seg" mid="7">Noin 140 000 ihmistä saa joka vuosi sydänkohtauksen Englannissa, ja neljännes näistä saa toisen kohtauksen tai aivohalvauksen.</mrk></target><sdl:seg-defs><sdl:seg id="7" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">nLX1kdHRRFQrAdhdTGDbT6LNzZc=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/09/2017 11:32:02</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/09/2017 11:57:59</sdl:value><sdl:value key="SDL:OriginalTranslationHash">520211645</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="2bfc5dce-16e3-4db5-8c00-c5513f7bffef"><source><x id="13"/>
<x id="14"/></source></trans-unit><trans-unit id="c4fc1769-9beb-4341-a538-665f662d280f"><source>Heart attacks and strokes are caused by the build-up of fatty material in artery walls to form a plaque.</source><seg-source><mrk mtype="seg" mid="8">Heart attacks and strokes are caused by the build-up of fatty material in artery walls to form a plaque.</mrk></seg-source><target><mrk mtype="seg" mid="8">Sydänkohtaukset ja aivohalvaukset johtuvat valtimon seinään kertyneestä rasva-aineksesta, joka muodostaa ahtaumia.</mrk></target><sdl:seg-defs><sdl:seg id="8" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">CyFnPcyOq+HmVfKuoAyjjD2k6nM=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/09/2017 11:35:21</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/09/2017 11:35:21</sdl:value><sdl:value key="SDL:OriginalTranslationHash">-1587608727</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="21100902-9599-4e8c-8192-84e09b2dbb45"><source><x id="15"/>
<x id="16"/></source></trans-unit><trans-unit id="11ef1708-98e2-46e2-907e-2663d48fa48c"><source>If the plaque breaks apart it can cause a blood clot, blocking blood to the heart causing a heart attack.</source><seg-source><mrk mtype="seg" mid="9">If the plaque breaks apart it can cause a blood clot, blocking blood to the heart causing a heart attack.</mrk></seg-source><target><mrk mtype="seg" mid="9">Jos ahtauma repeää, se voi aiheuttaa verihyytymän, joka estää verenkierron sydämeen aiheuttaen sydänkohtauksen.</mrk></target><sdl:seg-defs><sdl:seg id="9" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">hVcPozq+b6Vye352A9+Gh0+i4mQ=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/09/2017 11:36:24</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/09/2017 11:36:24</sdl:value><sdl:value key="SDL:OriginalTranslationHash">373722314</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="d2ac471f-5bb4-4945-b7c5-a2c8b7f900a7"><source><x id="17"/>
<x id="18"/></source></trans-unit><trans-unit id="f5885493-c29b-4e17-9869-adf69eb17986"><source>And if the clot dislodges it can travel in the blood stream and block blood flow to the brain, causing a stroke.</source><seg-source><mrk mtype="seg" mid="10">And if the clot dislodges it can travel in the blood stream and block blood flow to the brain, causing a stroke.</mrk></seg-source><target><mrk mtype="seg" mid="10">Jos hyytymä irtoaa, se voi kulkea veren mukana ja katkaista verenkierron aivoihin aiheuttaen aivohalvauksen.</mrk></target><sdl:seg-defs><sdl:seg id="10" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">e6GA/FXDVgsEc5kgP8X4Jt53bdQ=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/09/2017 11:37:26</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/09/2017 11:37:26</sdl:value><sdl:value key="SDL:OriginalTranslationHash">-101543352</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="ff7c8543-b527-424d-bef6-2a07afe5f6fa"><source><x id="19"/>
<x id="20"/></source></trans-unit><trans-unit id="101044eb-d36e-4678-93eb-be6352b3c2e4"><source>People who have already have one attack are at a higher risk of having another.</source><seg-source><mrk mtype="seg" mid="11">People who have already have one attack are at a higher risk of having another.</mrk></seg-source><target><mrk mtype="seg" mid="11">Henkilöillä jotka ovat jo saaneet yhden kohtauksen, on kohonnut riski saada toinen.</mrk></target><sdl:seg-defs><sdl:seg id="11" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">nktoiQwPu11DwmHd4LP91TaMZbA=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/09/2017 11:37:59</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/09/2017 11:37:59</sdl:value><sdl:value key="SDL:OriginalTranslationHash">-1761590829</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="c3e3efff-c19c-4009-bc56-cf53e954d73b"><source><x id="21"/>
<x id="22"/></source></trans-unit><trans-unit id="e45bd4f0-2f4e-4606-915a-2470f3124dab"><source>Ticagrelor, which is made by UK firm AstraZeneca and sold under the trade name Brilique, reduces this risk by making clots less likely.</source><seg-source><mrk mtype="seg" mid="12">Ticagrelor, which is made by UK firm AstraZeneca and sold under the trade name Brilique, reduces this risk by making clots less likely.</mrk></seg-source><target><mrk mtype="seg" mid="12">Ticagrelor, jota valmistaa isobritannialainen yritys AstraZeneca, ja jota myydään kauppanimellä Brilique, alentaa tätä riskiä tekemällä hyytymistä vähemmän todennäköisiä.</mrk></target><sdl:seg-defs><sdl:seg id="12" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">SlFEQtAxZ28i3K6hjegszmRmki8=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/09/2017 11:39:55</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/09/2017 11:39:55</sdl:value><sdl:value key="SDL:OriginalTranslationHash">-850079176</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="7495525b-35a9-42b1-8e40-d1006df2d0eb"><source><x id="23"/>
<x id="24"/></source></trans-unit><trans-unit id="ab558502-9bca-4475-a055-88031c1d8325"><source>The draft NICE guidance, published today, recommends that people be given 90 mg of ticagrelor for 12 months, followed by 60mg along with aspirin twice a day for another three years.</source><seg-source><mrk mtype="seg" mid="13">The draft NICE guidance, published today, recommends that people be given 90 mg of ticagrelor for 12 months, followed by 60mg along with aspirin twice a day for another three years.</mrk></seg-source><target><mrk mtype="seg" mid="13">Tänään julkaistussa NICE:n ohjeistusluonnoksessa suositellaan, että ihmisille annetaan 90 mg ticagreloria 12 kuukauden ajan, mitä seuraa 60 mg aspiriinin kanssa otettuna kahdesti päivässä seuraavien kahden vuoden ajan.</mrk></target><sdl:seg-defs><sdl:seg id="13" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">dzLQlzg7wWQRd33V3AGWCyMeqW0=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/09/2017 11:42:34</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/09/2017 11:42:34</sdl:value><sdl:value key="SDL:OriginalTranslationHash">-1062430786</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="abccb3ca-fe0a-4e15-ab10-10c07e332549"><source><x id="25"/>
<x id="26"/></source></trans-unit><trans-unit id="4b8d2edb-303c-4b73-b0a3-4e7c06dc18f9"><source>Professor Carole Longson, director at the NICE health technology evaluation centre, said: &quot;Despite the availability of effective secondary prevention treatments, as many as a quarter of people who have had a heart attack go on to have another heart attack or stroke - often with devastating consequences.&quot;</source><seg-source><mrk mtype="seg" mid="14">Professor Carole Longson, director at the NICE health technology evaluation centre, said:</mrk> <mrk mtype="seg" mid="15">&quot;Despite the availability of effective secondary prevention treatments, as many as a quarter of people who have had a heart attack go on to have another heart attack or stroke - often with devastating consequences.&quot;</mrk></seg-source><target><mrk mtype="seg" mid="14">Professori Carole Longson, NICE:n terveysteknologian arviointikeskuksen johtaja, sanoi:</mrk> <mrk mtype="seg" mid="15">”Huolimatta tehokkaiden etenemistä ehkäisevien hoitojen saatavuudesta, jopa neljännes sydänkohtauksen saaneista ihmisistä saavat myöhemmin toisen sydänkohtauksen tai aivohalvauksen, joiden seuraukset ovat usein tuhoisia.”</mrk></target><sdl:seg-defs><sdl:seg id="14" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">PIipoByJiCgGUeR8IANRtZ82cnI=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/09/2017 11:43:34</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/09/2017 11:43:34</sdl:value><sdl:value key="SDL:OriginalTranslationHash">675892704</sdl:value></sdl:seg><sdl:seg id="15" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">jgPajEue9LUJHeqJtIawzQAsQGw=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/09/2017 11:49:34</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/09/2017 11:49:34</sdl:value><sdl:value key="SDL:OriginalTranslationHash">-1224132012</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="d5790d9a-d75c-45ab-ae84-9c4e0cc1dc1d"><source><x id="27"/>
<x id="28"/></source></trans-unit><trans-unit id="ba1ca545-2ebd-49ba-b484-7fa175b5b8e9"><source>Fear of a recurrence can have a significant negative impact on a person&apos;s quality of life.</source><seg-source><mrk mtype="seg" mid="16">Fear of a recurrence can have a significant negative impact on a person&apos;s quality of life.</mrk></seg-source><target><mrk mtype="seg" mid="16">Uusiutumisen pelolla voi olla huomattava negatiivinen vaikutus henkilön elämänlaatuun.</mrk></target><sdl:seg-defs><sdl:seg id="16" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">UGd25EBiszOSjxQJ2LWjDkN44EI=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/09/2017 11:50:02</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/09/2017 11:50:02</sdl:value><sdl:value key="SDL:OriginalTranslationHash">1983565588</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="d3122f41-1de6-4063-9109-29e520e0fce9"><source><x id="29"/>
<x id="30"/></source></trans-unit><trans-unit id="41580abd-ad7d-40d0-a0c8-2f862f29fd69"><source>The evidence shows that ticagrelor, in combination with aspirin, is effective at reducing the risk of further heart attacks and strokes in people who have already had a heart attack.</source><seg-source><mrk mtype="seg" mid="17">The evidence shows that ticagrelor, in combination with aspirin, is effective at reducing the risk of further heart attacks and strokes in people who have already had a heart attack.</mrk></seg-source><target><mrk mtype="seg" mid="17">Todistusaineisto osoittaa, että ticagrelor yhdessä aspiriinin kanssa on tehokas laskemaan myöhempien sydänkohtausten ja aivohalvausten riskiä ihmisillä, joilla on jo ollut sydänkohtaus.</mrk></target><sdl:seg-defs><sdl:seg id="17" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">p+al6KM5YGM1Sj8zDLzBm0COq7o=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/09/2017 11:51:37</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/09/2017 11:51:37</sdl:value><sdl:value key="SDL:OriginalTranslationHash">1756097303</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="3811dfa1-e793-4f02-8889-e3ddf1346406"><source><x id="31"/>
<x id="32"/></source></trans-unit><trans-unit id="126aea38-d88b-4e89-832d-724f90ce12e3"><source>In provisionally recommending ticagrelor we are pleased to be able to increase the treatment options available to the many thousands of people who stand to benefit from it.</source><seg-source><mrk mtype="seg" mid="18">In provisionally recommending ticagrelor we are pleased to be able to increase the treatment options available to the many thousands of people who stand to benefit from it.</mrk></seg-source><target><mrk mtype="seg" mid="18">Suositellessamme alustavasti ticagreloria olemme tyytyväisiä voidessamme lisätä saatavilla olevia hoitovaihtoehtoja useille tuhansille niistä mahdollisesti hyötyville ihmisille.</mrk></target><sdl:seg-defs><sdl:seg id="18" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">UKYNWrRr132fOsBJSmQ1Nxh//3U=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/09/2017 11:52:48</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/09/2017 11:58:00</sdl:value><sdl:value key="SDL:OriginalTranslationHash">903305005</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="27bcde23-566b-4909-9835-b8a97b0cf538"><source><x id="33"/>
<x id="34"/></source></trans-unit><trans-unit id="4b44ff03-a451-4077-bb11-e5a058ca859f"><source>Because information on the efficacy and safety of ticagrelor - particularly the risk of bleeding - beyond three years is limited, the draft guidance does not recommend treatment with it beyond that period.</source><seg-source><mrk mtype="seg" mid="19">Because information on the efficacy and safety of ticagrelor - particularly the risk of bleeding - beyond three years is limited, the draft guidance does not recommend treatment with it beyond that period.</mrk></seg-source><target><mrk mtype="seg" mid="19">Koska ticagrelorin tehokkuutta ja turvallisuutta koskevat tiedot - erityisesti mitä tulee verenvuodon riskiin - yli kolmen vuoden ajanjaksoilla ovat rajoitetut, ohjeistusluonnoksessa ei suositella hoitoa pidempään, kuin tämän ajanjakson ajan.</mrk></target><sdl:seg-defs><sdl:seg id="19" conf="Translated" origin="interactive"><sdl:value key="SegmentIdentityHash">ZXpfyODkdEWbD+B4n9pUySafBjk=</sdl:value><sdl:value key="created_by">ECTO-1\134</sdl:value><sdl:value key="created_on">02/09/2017 11:57:16</sdl:value><sdl:value key="last_modified_by">ECTO-1\134</sdl:value><sdl:value key="modified_on">02/09/2017 11:57:16</sdl:value><sdl:value key="SDL:OriginalTranslationHash">-1397636297</sdl:value></sdl:seg></sdl:seg-defs></trans-unit><trans-unit translate="no" id="18d2384a-1518-4929-ac9d-91b16a44577c"><source><x id="35"/>
</source></trans-unit></body></file></xliff>